IP Library Granted Patent US 7,892,567
Granted Patent B2
US 7,892,567 · App. 12/243,769 · Granted Feb 22, 2011

Methods and compositions for immunization against chlamydial infection and disease

Assignee: Board of Regents, The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,892,567
App. No.
12/243,769
Granted
Feb 22, 2011
Kind
B2
Abstract

The present invention provides Chlamydia proteins and compositions and methods of use in the treatment/prevention of chlamydial infection in a subject, for eliciting an immune response in a subject and for reducing the likelihood of infertility and reducing the incidence and/or degree of hydrosalpinx due to Chlamydia infection in a subject.

Claims (8)

1. A method of reducing the likelihood of infertility due to Chlamydia infection in a subject, comprising administering to the subject a composition comprising an effective amount of a chlamydial protease-like activity factor (CPAF) protein or an immunogenic fragment thereof, thereby treating Chlamydia infection, which thereby reduces the likelihood of infertility caused by said Chlamydia infection.

2. A method of reducing the likelihood of infertility due to Chlamydia infection in a subject, comprising administering to the subject a composition comprising:

a) an effective amount of a chlamydial protease-like activity factor (CPAF) protein or an immunogenic fragment thereof, and

b) an effective amount of a different chlamydial protein or immunogenic fragment thereof, thereby treating Chlamydia infection, which thereby reduces the likelihood of infertility caused by said Chlamydia infection.

3. The method of claim 1 , further comprising administering an adjuvant to the subject.

4. The method of claim 2 , further comprising administering an adjuvant to the subject.

5. The method of claim 3 , wherein the adjuvant is selected from the group consisting of: IL-12, CpG oligodeoxynucleotides, alum, Montanide ISA 720 and any combination thereof.

6. The method of claim 4 , wherein the adjuvant is selected from the group consisting of: IL-12, CpG oligodeoxynucleotides, alum, Montanide ISA 720 and any combination thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 27, 2009
From: UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022324/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2008
From: ARULANANDAM, BERNARD P.; MURTHY, ASHLESH K.; ZHONG, GUANGMING
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 021992/0842 →
Continuity (2)
Provisional Application 60976636 · Oct 1, 2007
Related Publication 20090098165A1 · Apr 16, 2009